Jay Steingrub to Infusions, Intravenous
This is a "connection" page, showing publications Jay Steingrub has written about Infusions, Intravenous.
Connection Strength
0.080
-
Self WH, Semler MW, Bellomo R, Brown SM, deBoisblanc BP, Exline MC, Ginde AA, Grissom CK, Janz DR, Jones AE, Liu KD, Macdonald SPJ, Miller CD, Park PK, Reineck LA, Rice TW, Steingrub JS, Talmor D, Yealy DM, Douglas IS, Shapiro NI. Liberal Versus Restrictive Intravenous Fluid Therapy for Early Septic Shock: Rationale for a?Randomized Trial. Ann Emerg Med. 2018 10; 72(4):457-466.
Score: 0.036
-
Morris AH, Orme J, Truwit JD, Steingrub J, Grissom C, Lee KH, Li GL, Thompson BT, Brower R, Tidswell M, Bernard GR, Sorenson D, Sward K, Zheng H, Schoenfeld D, Warner H. A replicable method for blood glucose control in critically Ill patients. Crit Care Med. 2008 Jun; 36(6):1787-95.
Score: 0.018
-
Zeiher BG, Steingrub J, Laterre PF, Dmitrienko A, Fukiishi Y, Abraham E. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med. 2005 Aug; 33(8):1741-8.
Score: 0.015
-
Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy H, Nelson L, Rumbak M, Steingrub J, Taylor J, Park YC, Hynds JM, Freitag J. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med. 1999 Aug; 27(8):1478-85.
Score: 0.010